India Astrazeneca
- All
- News
- Videos
-
What Is Imfinzi Durvalumab, The Cancer Drug That Just Got Approval For Use In India?
- Wednesday February 11, 2026
- Health | Written by Varsha Vats
Unlike traditional chemotherapy, which attacks rapidly dividing cells (both healthy and cancerous), Durvalumab helps your own immune system recognise and destroy cancer cells. It targets a specific protein called PD-L1.
-
www.ndtv.com
-
Cancer Drug Imfinzi Gets Indian Regulator's Approval For Use In First-Line Treatment
- Tuesday February 10, 2026
- Health | Indo-Asian News Service
AstraZeneca Pharma India Limited on Tuesday said it has received permission from the Central Drugs Standard Control Organisation to sell and distribute Durvalumab solution for infusion used in cancer treatment.
-
www.ndtv.com
-
Failure of AstraZeneca Trial Big Blow For Anti-Addiction Drugs: Report
- Wednesday November 27, 2024
- India News | Indo-Asian News Service
The failure of the trial of the drug AZD4041 by pharma giant AstraZeneca, to combat opioid use disorder (OUD), highlights the challenges in developing non-opioid medications that treat addiction and withdrawal, according to a report.
-
www.ndtv.com
-
Covaxin Has Excellent Safety Record: Bharat Biotech On Study Citing Risks
- Thursday May 16, 2024
- India News | Indo-Asian News Service
The study, led by Banaras Hindu University (BHU), claimed that Covaxin raised the rare risk of stroke, and Guillain-Barre syndrome, among others.
-
www.ndtv.com
-
AstraZeneca Covid Vaccine Linked To Another Fatal Blood Clotting Disorder
- Thursday May 16, 2024
- World News | Indo-Asian News Service
AstraZeneca's Covid-19 vaccine, made in collaboration with Oxford University has been found to raise the risk of vaccine-induced immune thrombocytopenia and thrombosis (VITT) -- a rare but fatal blood clotting disorder, claimed researchers today.
-
www.ndtv.com
-
Covishield Side Effects: Doctors' Group Urges Centre To Review All Covid Vaccines
- Friday May 10, 2024
- India News | Press Trust of India
In the wake of pharmaceutical giant AstraZeneca admitting in a UK court that its Covid vaccine can cause blood clots in rare cases, a group of doctors on Thursday expressed deep concern over the safety of the Covishield vaccine.
-
www.ndtv.com
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
- Wednesday May 8, 2024
- India News | Reported by Vishnu Som
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
www.ndtv.com
-
Supreme Court Agrees To Hear Plea Over Covishield Side-Effect Concern
- Monday May 6, 2024
- India News | Reported by Ashish Bhargava
The Supreme Court will hear a petition on a rare side-effect associated with the COVID vaccine developed jointly by British pharma giant AstraZeneca and Oxford University, manufactured by the Serum Institute of India and sold in India as Covishield.
-
www.ndtv.com
-
Couple Allege Daughter Died After Taking Covishield, To Sue AstraZeneca
- Friday May 3, 2024
- India News | NDTV News Desk
The parents of a young woman who died allegedly after being given Covishield are planning to sue the world's largest vaccine maker and the British pharma giant that had developed the vaccine during the Covid pandemic.
-
www.ndtv.com
-
No Side Effects From Our Vaccine: Covaxin Maker Amid AstraZeneca Row
- Thursday May 2, 2024
- India News | NDTV Newsdesk
The Covaxin was developed with a single-minded focus on safety first, said its maker Bharat Biotech on Thursday, days after British pharma giant AstraZeneca admitted that its Covid vaccine can cause rare side effects.
-
www.ndtv.com
-
What Is Imfinzi Durvalumab, The Cancer Drug That Just Got Approval For Use In India?
- Wednesday February 11, 2026
- Health | Written by Varsha Vats
Unlike traditional chemotherapy, which attacks rapidly dividing cells (both healthy and cancerous), Durvalumab helps your own immune system recognise and destroy cancer cells. It targets a specific protein called PD-L1.
-
www.ndtv.com
-
Cancer Drug Imfinzi Gets Indian Regulator's Approval For Use In First-Line Treatment
- Tuesday February 10, 2026
- Health | Indo-Asian News Service
AstraZeneca Pharma India Limited on Tuesday said it has received permission from the Central Drugs Standard Control Organisation to sell and distribute Durvalumab solution for infusion used in cancer treatment.
-
www.ndtv.com
-
Failure of AstraZeneca Trial Big Blow For Anti-Addiction Drugs: Report
- Wednesday November 27, 2024
- India News | Indo-Asian News Service
The failure of the trial of the drug AZD4041 by pharma giant AstraZeneca, to combat opioid use disorder (OUD), highlights the challenges in developing non-opioid medications that treat addiction and withdrawal, according to a report.
-
www.ndtv.com
-
Covaxin Has Excellent Safety Record: Bharat Biotech On Study Citing Risks
- Thursday May 16, 2024
- India News | Indo-Asian News Service
The study, led by Banaras Hindu University (BHU), claimed that Covaxin raised the rare risk of stroke, and Guillain-Barre syndrome, among others.
-
www.ndtv.com
-
AstraZeneca Covid Vaccine Linked To Another Fatal Blood Clotting Disorder
- Thursday May 16, 2024
- World News | Indo-Asian News Service
AstraZeneca's Covid-19 vaccine, made in collaboration with Oxford University has been found to raise the risk of vaccine-induced immune thrombocytopenia and thrombosis (VITT) -- a rare but fatal blood clotting disorder, claimed researchers today.
-
www.ndtv.com
-
Covishield Side Effects: Doctors' Group Urges Centre To Review All Covid Vaccines
- Friday May 10, 2024
- India News | Press Trust of India
In the wake of pharmaceutical giant AstraZeneca admitting in a UK court that its Covid vaccine can cause blood clots in rare cases, a group of doctors on Thursday expressed deep concern over the safety of the Covishield vaccine.
-
www.ndtv.com
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
- Wednesday May 8, 2024
- India News | Reported by Vishnu Som
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
www.ndtv.com
-
Supreme Court Agrees To Hear Plea Over Covishield Side-Effect Concern
- Monday May 6, 2024
- India News | Reported by Ashish Bhargava
The Supreme Court will hear a petition on a rare side-effect associated with the COVID vaccine developed jointly by British pharma giant AstraZeneca and Oxford University, manufactured by the Serum Institute of India and sold in India as Covishield.
-
www.ndtv.com
-
Couple Allege Daughter Died After Taking Covishield, To Sue AstraZeneca
- Friday May 3, 2024
- India News | NDTV News Desk
The parents of a young woman who died allegedly after being given Covishield are planning to sue the world's largest vaccine maker and the British pharma giant that had developed the vaccine during the Covid pandemic.
-
www.ndtv.com
-
No Side Effects From Our Vaccine: Covaxin Maker Amid AstraZeneca Row
- Thursday May 2, 2024
- India News | NDTV Newsdesk
The Covaxin was developed with a single-minded focus on safety first, said its maker Bharat Biotech on Thursday, days after British pharma giant AstraZeneca admitted that its Covid vaccine can cause rare side effects.
-
www.ndtv.com